Standardized medical therapy targeting vascular risk factors and stroke prevention
Standardized medical therapy targeting vascular risk factors and stroke prevention: Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines
Study summary
Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Adults aged 18 to 80 years.
2. Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.
3. Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.
4. Written informed consent obtained from the participant or a legal representative.
Exclusion Criteria:
1. Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities.
2. More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.
3. Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.
4. Contraindications to antiplatelet therapy or statins.
5. Inability to undergo MRI due to metal implants or claustrophobia.
Primary outcome measure(s)
ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment. — 12 months the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.